1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...

Majority of adverse events were mild-to-moderate with no fatalities reported. Evidence Rating Level: 1 (Excellent) Study ...

In two cohorts from the UK Biobank and the National Health and Nutrition Examination Survey (NHANES), there was an increased ...

In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a ...

In a retrospective analysis of 59,875 patients with metastatic prostate cancer, varying prognoses were found primarily ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Machine learning (ML) models developed by Lehmann and colleagues used driving characteristics and head motion data to detect ...

In veterans with spinal cord injuries, exoskeletons showed no clear benefits (medical, physical or psychological) compared to ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

Relutrigine resulted in a 46% reduction in seizures and seizure freedom in 30% of patients. Patients also experienced ...

Chronic pain syndromes including fibromyalgia, dry eye disease, and irritable bowel syndrome showed no significant ...